A5079916229- Health Systems, Economic Evaluations, Quality of Life
- Treatment of Major Depression
- Psychedelics and Drug Studies
- Chemical synthesis and alkaloids
- Pharmaceutical Economics and Policy
- Complementary and Alternative Medicine Studies
- Delphi Technique in Research
- Biotechnology and Related Fields
- Pharmaceutical studies and practices
- Bipolar Disorder and Treatment
- Meta-analysis and systematic reviews
- Cholinesterase and Neurodegenerative Diseases
- CRISPR and Genetic Engineering
- Pain Management and Placebo Effect
- Diverse academic research themes
- Digital Mental Health Interventions
- Maternal Mental Health During Pregnancy and Postpartum
- Computational Drug Discovery Methods
- Neuroethics, Human Enhancement, Biomedical Innovations
- Forensic Toxicology and Drug Analysis
- Obstructive Sleep Apnea Research
- Stress and Burnout Research
- Neuroscience and Neural Engineering
- Sleep and Wakefulness Research
- Genomics and Rare Diseases
Inserm
2017-2025
Centre de recherche en Epidémiologie et Santé des Populations
2019-2025
European Medicines Agency
2010-2025
Institut Gustave Roussy
2025
Université Paris-Saclay
2025
Université de Versailles Saint-Quentin-en-Yvelines
2025
Verasci (United States)
2022
University of California, Los Angeles
2022
Janssen (United States)
2022
Neurocrine Biosciences (United States)
2022
Psychedelic drugs including psilocybin and LSD are undergoing clinical trials for a range of psychiatric neurological conditions, have particularly shown substantial promise in phase 2 studies depression. In this article we outline key knowledge gaps that may be imperative successful implementation psychedelic as medicines identified by members the European College Neuropsychopharmacology at New Frontiers Meeting Nice (2023). Key themes include pharmacokinetic pharmacodynamic...
Neurosciences clinical trials continue to have notoriously high failure rates. Appropriate outcomes selection in early is key maximizing the likelihood of identifying new treatments psychiatry and neurology. The field lacks good standards for designing outcome strategies, therefore Outcomes Research Group was formed develop promote practices selection. This article describes first published guidance on standardization process neuroscience. A minimal step defined starting as possible,...
Abstract Background Recent years show an exponential increased interest (“renaissance”) in the use of psychedelics for treatment mental disorders and broader. Some these treatments, such as psilocybin depression, are process formal regulation by regulatory bodies US (FDA) Europe (EMA), on brink real-world implementation. In slipstream developments increasing commercial initiatives taking shape. The European Psychiatric Association (EPA) acknowledges both therapeutic potential psychedelic...
A legislative framework introducing European public health measures on orphan medicinal products came into force in the Union April 2000. The aim of legislation is to stimulate research and development for rare diseases by providing incentives sponsors. Incentives include, among others, an unreserved access centralized procedure with a 10-year period market exclusivity fee reductions including free scientific advice drug development. Nine years after implementation legislation, more than 690...
According to the World Health Organization (WHO), depressive disorders are currently considered as one of most disabling medical conditions in world with highest disability-adjusted life years [1] and this situation has apparently been further worsened during COVID-19 pandemic [2]. Up two thirds patients major (MDD) do not achieve full remission following an adequate first line standard care and/or experience residual symptoms such anxiety, impaired cognition, fatigue, sleep disturbance, or...
Neurosciences clinical trials continue to have notoriously high failure rates. Appropriate outcomes selection in early is key maximizing the likelihood of identifying new treatments psychiatry and neurology. The field lacks good standards for designing outcome strategies, therefore Outcomes Research Group was formed develop promote practices selection. This article describes first published guidance on standardization process neuroscience. A minimal step defined starting as possible,...